Business Wire

Boehringer Ingelheim Launches the First-Ever Registered Stem Cell-Based Veterinary Medicine

Del

Boehringer Ingelheim launches Arti-Cell® Forte in Europe for the ‘reduction of mild to moderate recurrent lameness associated with non-septic joint inflammation in horses’.

Equine lameness is truly common and impacts horse performance as well as equine welfare1. Current treatment is not satisfactory for all cases and there is a clear need for innovation and new treatment options. Hence, the significant interest in treatment beyond symptoms, namely combatting the underlying root cause.

Arti-Cell® Forte is a groundbreaking first-ever approved therapy, developed towards targeting lameness, utilising specifically primed, chondrogenic induced stem cells. Arti-Cell® Forte comes in an ultra-low frozen ready-to-use presentation.

Boehringer Ingelheim and Global Stem cell Technology (GST), that formed a partnership last year, have the same ambition to bring new treatments and solutions to improve animal health; therefore, Arti-Cell® Forte was specifically designed for horses to provide a convenient and long-term2 solution for recurrent lameness.

“A quarter of the entire equine population1 develops osteoarthritis at some point in their life. Priming the cells towards cartilage aids them to deliver the right activities in the affected joint,” says Jan Spaas, CEO of GST. “We are absolutely delighted with our first marketing authorisation from the European Commission and the first stem cell-based product in Animal Health. We are sure that with our partner Boehringer Ingelheim this product will become a game changer in equine health.”

Dr. Erich Schoett, Head of the Global Strategic Business Unit Equine at Boehringer Ingelheim, shares: “We are proud to continue to set new standards of care for horses to optimise their health and well-being in partnership with veterinarians. Early disease detection and early treatment are key to ensure that horses are healthy and live longer, happier lives. Arti-Cell® Forte as the first-ever approved stem cell-based product offers to veterinarians and horse owners a ready-to-use solution to help raising the health and quality of life for horses with mild to moderate recurrent lameness”.

Following the scientific review by the European Medicines Agency2 and decision of EU marketing authorisation by the European Commission, Arti-Cell® Forte is now approved as a veterinary medicine for the treatment of equine lameness. It will be available from May and June 2019 onwards in a range of European Countries.

Intended audiences

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.

Please click on the link for ‘Notes to Editors’ and ‘References’:
http://www.boehringer-ingelheim.com/press-release/arti-cell-forte-stem-cell-based-veterinary-product

Contact information

Boehringer Ingelheim
Animal Health Communication
Tereza Urbankova
Phone: +49 170 9388827
Email: press@boehringer-ingelheim.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

The “One and Done” Era for Orphan Drugs: Evaluate Predicts 12% Growth, Driven by New Technologies, but Benefits Go to Big Pharma25.4.2019 07:00:00 CESTPressemelding

Scientific advancements will help propel the orphan drug market to a 12% CAGR to 2024, double the 6% rate expected for non-orphan products. In addition to recent breakthrough cell and gene therapy products like Yescarta and Luxturna, a number of “one and done” treatments for orphan diseases are approaching the market, including Novartis’s Zolgensma and bluebird bio’s Lentiglobin. The explosion of new technologies brings their high price points into greater focus — for example, the $425,000 per eye list price for Spark’s Luxturna is the value-based price agreed on with Spark and payers. In 2018, the mean cost for an orphan drug was 4.5 times that of a non-orphan product. Despite the clear advancements in treatment, however, those calling for reform of the Orphan Drug Act may gain further ammunition. Big pharma continues to entrench their position in the orphan market, as evidenced by Bristol-Myers Squibb’s bid for Celgene, Roche’s pending acquisition of Spark, and Novartis’s $8.7bn paym

NTT Group Increases Capital in NTT Global Data Centers Corp. to Further Strengthen Data Center Business25.4.2019 06:00:00 CESTPressemelding

NTT Communications Corporation (NTT Com), the ICT solutions and international communications business within the NTT Group (TOKYO:9432), NTT Urban Development Corporation, Nippon Telegraph and Telephone Corporation (NTT Corporation), NTT Finance Corporation announced today that it has increased its capital in NTT Global Data Centers Corporation (NTT GDC), a subsidiary company handling centralized global construction, management and equipment wholesales for NTT group data centers. NTT GDC is capitalized at 1.25 billion JPY, of which 60% will be had share by NTT Com. And three other NTT Group companies newly acquired shares in NTT GDC, namely, NTT Urban Development Corporation (20%), NTT Corporation (10%) and NTT Finance Corporation (10%), all as of today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190424006195/en/ NTT GDC oversees investment and asset-ownership functions for data center construction. Established last year

China Yiwu Imported Commodities Fair 2019 to Open in May25.4.2019 05:49:00 CESTPressemelding

China Yiwu Imported Commodities Fair 2019, the professional platform for international small commodities to enter China, will open on May 23-26, 2019 at the Yiwu International Expo Center in China’s small commodities paradise Yiwu City. The Fair of this year will cover an exhibition area of over 50,000 square meters, providing 2,000 international standard booths in 4 exhibition zones, namely Asia Pavilion I, Asia Pavilion II, European Pavilion and America-Australia-Africa & Cross-border Trade Pavilion. The imported commodities to be displayed will include household items, maternal and child supplies, beauty and personal care, crafts, home appliances, food and beverage, health and nutrition, fashion accessories, creative toys, stationery, sports goods, clothing and accessories. The Fair is expected to attract over 1,500 business companies and organizations from over 100 countries and regions across the world. The number of visitors and buyers will exceed 120,000. The Import Commodities

Biomedical Software Startup BostonGene Secures $50M in Series A Financing from NEC25.4.2019 01:00:00 CESTPressemelding

NEC Corporation (NEC; TSE: 6701) and BostonGene Corporation (BostonGene), a Boston, Mass-based biomedical software company, today announced a US$50M series A strategic investment in BostonGene by NEC. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190424006170/en/ BostonGene, a pioneer in the use of biomedical software for advanced patient analysis, has discovered, developed, and patented a holistic approach to cancer treatment by defining the optimal therapy combination for individual patients, with a particular focus on immuno- and targeted therapies. BostonGene’s solution includes: Genome and transcriptome sequencing methods to create a patient’s molecular profile. Algorithms that estimate the immune fitness and cancer characteristics of a patient. A continuously updated expert-curated and Artificial Intelligence (AI)-driven database of cancer research and clinical information. Cloud-native software that delivers a patien

ABS, Google Cloud and SoftServe Partner to Demonstrate Feasibility of AI-enabled Corrosion Detection24.4.2019 15:57:00 CESTPressemelding

ABS, Google Cloud and SoftServe completed a pilot project applying artificial intelligence (AI) models to detect levels of corrosion and coating breakdown on ships and offshore structures. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190424005822/en/ ABS, Google Cloud and SoftServe Partner to Demonstrate Feasibility of AI-enabled Corrosion Detection (Photo: Business Wire) The project successfully demonstrated the accuracy of AI in detecting and assessing structural anomalies commonly found during visual inspection. AI techniques could be further used to analyze images over time to understand corrosion and coating breakdown trends. “Digital innovation in AI will change how surveys and maintenance strategies are executed, driving more condition-based approaches to class and maintenance,” said ABS Chairman, President and CEO, Christopher J. Wiernicki. “We are building a future in which digital tools can remotely assess the co

The 2019 .eu Web Awards Launch Today24.4.2019 14:13:00 CESTPressemelding

The .eu Web Awards is an online competition designed to acknowledge the best websites using the .eu or .ею extensions in five diverse categories. Anyone who is eligible according to the .eu Web Awards rules can nominate their favourite .eu or .ею. website. This includes .eu and .ею domain name holders themselves, who can nominate their very own website for participation in the .eu Web Awards. “After the successful edition of 2018 with 130 nominations and nearly 10 000 votes for excellent sites, we look forward to awarding the best websites in the five categories”- Giovanni Seppia, EURid External Relations Manager. The 15 finalists will be invited to the .eu Web Awards gala in Brussels on 20 November 2019 where the five winners – one per category – will be announced. The winners will receive a prestigious award package, including a two-month billboard advertising campaign in Brussels Airport, a custom video produced by EURid for their promotional purposes, and a custom trophy and person